TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36569610
Drug: Short-course (SC)
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course (SC) antidepressant therapy
Study: 36569610
Drug: Long-course (LC)
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course (LC) antidepressant therapy
Study: 36569610
Drug: 2-week FM
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week FM therapy
Study: 36569610
Drug: 4-week FM
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week FM therapy
Study: 36569905
Drug: AK104 (PD-1/CTLA-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK104 (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy (mXELOX)
Study: 36569905
Drug: AK104 (PD-1/CTLA-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK104 (PD-1/CTLA-4 bispecific antibody) combined with single-drug capecitabine therapy
Study: 36569905
Drug: Steroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid therapy combined with mycophenolate mofetil
Study: 36569905
Drug: AK104 rechallenged
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK104 rechallenged after hormone therapy
Study: 36570150
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet supplemented with probiotics (10 unspecified dosage)
Study: 36570498
Drug: High-Intensity Interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Interval Training (HIIT) 3 times a week + Treatment as Usual (TAU)
Study: 36570649
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg once daily for 3 months
Study: 36571164
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) for patients with underlying ICAD
Study: 36571164
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) for patients without underlying ICAD
Study: 36571171
Drug: Combined chlorpheniramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chlorpheniramine 10 mg and ranitidine 50 mg
Study: 36571611
Drug: Topical cetirizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cetirizine with minoxidil
Study: 36571611
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil with placebo
Study: 36571770
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 1200 mg intravenously every 2 weeks until confirmed progression, unacceptable toxicity, or trial withdrawal.
Study: 36571826
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy applied 10 minutes before port needle removal
Study: 36572501
Drug: Low-dose chest
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chest CT scan
Study: 36572571
Drug: Capivasertib 400
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capivasertib 400 mg (orally, twice daily, with an intermittent schedule of 4 days on, 3 days off) plus abiraterone acetate 1000 mg (orally administered once daily) and prednisone 5 mg (twice daily)
Study: 36573071
Drug: Smiling is
Normalized name: IS-5MN
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Smiling is Fun (internet-based treatment)
Study: 36573071
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control phase)
Study: 36573651
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (racemic ketamine hydrochloride) administered over a 40-minute intravenous infusion, 2 times per week on nonconsecutive days for 4 weeks (8 sessions)
Study: 36573717
Drug: High-dose glimepiride
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glimepiride (2-4 mg/day)
Study: 36574256
Drug: 3-pronged COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-pronged COVID-19 vaccine messaging platform (4-minute video, 1-page flyer, scripted message from ED staff)
Study: 36574256
Drug: 3-pronged COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-pronged COVID-19 vaccine messaging platform
Study: 36574387
Drug: LNG/EE TDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG/EE TDS (delivering LNG 120 μg/day and EE 30 μg/day) for 12 weeks
Study: 36574434
Drug: Rapid glucose
Normalized name: Clotam Rapid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid glucose infusion (3 times 20 grams of glucose i.v. over 5 minutes)
Study: 36574434
Drug: Continuous glucose
Normalized name: sub-q infusion pump w/continuous glucose monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous glucose infusion (60 grams of glucose continuously over 3 hours)
Study: 36574590
Drug: Tolvaptan 15
Normalized name: tolvaptan 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 15 mg daily
Study: 39546129
Drug: 0.75% ruxolitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% ruxolitinib cream
Study: 36574595
Drug: vehicle to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle to 0.75% ruxolitinib cream
Study: 36574595
Drug: vehicle to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle to 1.5% ruxolitinib cream
Study: 36574595
Drug: ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ruxolitinib cream (both strengths)
Study: 36574828
Drug: Ambezim-G (trypsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambezim-G (trypsin 5mg-chymotrypsin 5 mg)
Study: 36574828
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ibuprofen and trypsin-chymotrypsin
Study: 36575175
Drug: Inhalation technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation technique observation
Study: 36575175
Drug: In-person observation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-person observation of inhalation technique
Study: 36575361
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus 8 Gy single fraction radiation therapy (RT)
Study: 36575390
Drug: Ultrasound-guided SHPN
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided SHPN using 3 ml 5% bupivacaine plus 20 ml 10% phenol
Study: 36575390
Drug: Fluoroscopic-guided SHPN
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopic-guided SHPN using 3 ml 5% bupivacaine plus 20 ml 10% phenol
Study: 36575394
Drug: Prior paracetamol
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior paracetamol intake
Study: 36575394
Drug: No prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prior paracetamol intake
Study: 36575425
Drug: Inhaled carbon
Normalized name: carbon dioxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled carbon dioxide (CO)
Study: 36575505
Drug: Pegloticase +
Normalized name: Pegloticase
DrugBank: Pegloticase (DB09208)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegloticase + oral methotrexate (15 mg/week) administered 4 weeks before and during pegloticase treatment (biweekly 8 mg infusion, ≤ 52 weeks)
Study: 36575513
Drug: Pyrotinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib (400 mg once daily) plus trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg) and docetaxel (100 mg/m2)
Study: 36575513
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg) and docetaxel (100 mg/m2)
Study: 36576091
Drug: Latanoprost (other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost (other formulations)
Study: 36576173
Drug: Avelumab plus
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab plus axitinib (avelumab 10 mg/kg every 2 weeks plus axitinib 5 mg twice daily)
Study: 36576191
Drug: Problem-Solving Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-Solving Therapy for Adherence and Depression (PST-AD) - 6 sessions
Study: 36576323
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (optimization of drug therapy)
Study: 36576342
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ≥17.2 g BZ mass and presence of BZ channels
Study: 36576547
Drug: Low-contrast-dose group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-contrast-dose group (n = 43)
Study: 36576547
Drug: Standard-contrast-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-contrast-dose group (n = 47)
Study: 36576860
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment for heavy menstrual bleeding
Study: 36577165
Drug: Sotorasib (first-in-class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotorasib (first-in-class KRAS inhibitor)
Study: 36577165
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm treatment (inferior to the best standard of care)
Study: 36578002
Drug: Intervention (SHHC-2.0):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (SHHC-2.0): Twice-weekly experiential classes focused on exercise, nutrition, and civic engagement.
Study: 36578040
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg rivaroxaban
Study: 36578069
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of intravenous phage (mixture of four anti-pseudomonal phages)
Study: 36578194
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg intravenously at weeks 0, 2, and 6 (induction therapy)
Study: 36578194
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg every 8 weeks during maintenance therapy
Study: 36578450
Drug: Occupational therapy-led
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy-led fall prevention intervention
Study: 36578832
Drug: 90-mg ticagrelor
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-mg ticagrelor
Study: 36578916
Drug: Oral Ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ferrous Sulphate (FS) 200 mg three times a day for 12 weeks
Study: 36579179
Drug: Swiss low
Normalized name: Swiss Kriss
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swiss low back acupuncture (SLBA) - 9-week therapy, 15 sessions total (weeks 1-6: two sessions/week, weeks 7-9: one session/week)
Study: 36579179
Drug: Standard acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard acupuncture (SA) - 9-week therapy, 15 sessions total (weeks 1-6: two sessions/week, weeks 7-9: one session/week)
Study: 36579349
Drug: Compound 7460-0250
Normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compound 7460-0250
Study: 36579443
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of intramuscular nandrolone decanoate every 15 days for 2 years
Study: 36579494
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin for 3 days
Study: 36579617
Drug: Ambrisentan low
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ambrisentan low dose
Study: 36579617
Drug: Ambrisentan high
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ambrisentan high dose
Study: 37332660
Drug: Ambrisentan (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan (both doses)
Study: 36579743
Drug: Brigatinib 180
Normalized name: brigatinib 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib 180 mg once daily (days 9-28)
Study: 36580029
Drug: Sucrosomial® iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrosomial® iron (60 mg/day for one month)
Study: 36580650
Drug: anaprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: anaprazole 20 mg once daily for 4 weeks
Study: 36580650
Drug: rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 10 mg + anaprazole placebo
Study: 36581186
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) 400 mg/100 mg twice daily for 14 days
Study: 36581413
Drug: Cochlear implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implant (CI) and hearing aid (HA) in a bimodal solution (CI+HA)
Study: 36581874
Drug: Preoperative carbohydrates
Normalized name: CARBOHYDRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative carbohydrates (CHO) supplement, 50 g carbohydrates orally the evening before surgery (20:00-24:00)
Study: 36581878
Drug: Efavirenz 50
Normalized name: efavirenz 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 50 mg
Study: 36581878
Drug: Efavirenz 200
Normalized name: efavirenz 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 200 mg
Study: 36581893
Drug: Metformin (n=194)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (n=194)
Study: 36581902
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) associated with pain neuroscience education (PNE) and clinical hypnosis (CH)
Study: 36581902
Drug: PNE, CH,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNE, CH, and sham therapy
Study: 36582243
Drug: Cavrotolimod (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavrotolimod (5, 10, 12.5, and 18.8 µg/kg)
Study: 36582297
Drug: Nintendo Switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintendo Switch RingFit Adventure (RFA) exergame-based exercise, details on dosage and duration not available.
Study: 36582423
Drug: Photon beam
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photon beam therapy (SCRT with photons)
Study: 36582742
Drug: NLRP3 variant
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLRP3 variant G-allele carriers
Study: 36583171
Drug: Niraparib 200
Normalized name: niraparib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 200 mg or 300 mg once daily continuously and anlotinib 10 mg (12 mg before protocol amendment) once daily on days 1-14 of each 21-day cycle until disease progression or intolerable toxicity.
Study: 36583350
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of activated complement
Study: 36583355
Drug: Finerenone 10
Normalized name: finerenone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 10 mg once daily for 90 days
Study: 36583355
Drug: Finerenone 15
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Finerenone 15 mg once daily for 90 days
Study: 36583355
Drug: Finerenone 20
Normalized name: finerenone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 20 mg once daily for 90 days
Study: 36584053
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with ropivacaine 0.75%, 0.35 ml.kg-1
Study: 36584248
Drug: α-Lipoic Acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-Lipoic Acid (ALA) 100 mg/d
Study: 36584579
Drug: Nerve-growth-factor injection
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve-growth-factor injection
Study: 36584711
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning model using early treatment data from STAR*D (baseline and first follow up) to predict remission rates at treatment step 1.
Study: 36584711
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning model using early treatment data from STAR*D to predict remission rates at treatment step 2.
Study: 36584711
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning model using early treatment data from STAR*D to predict remission rates at treatment step 3.
Study: 36584835
Drug: Discontinued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued treatment early
Study: 36585127
Drug: Abatacept 125
Normalized name: abatacept 125 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept 125 mg/mL weekly subcutaneous injections
Study: 36585130
Drug: Enalapril (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (starting at 2.5 mg two times per day, titrating up to a maximum dose of 10 mg two times per day)
Study: 36585130
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (high-dose anthracycline-based chemotherapy)
Study: 36585137
Drug: SARS-CoV-2 vaccine
Normalized name: SARS-CoV-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 vaccine
Study: 36585139
Drug: Daily synbiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily synbiotic intervention (combining human milk oligosaccharide and probiotic)
Study: 36585147
Drug: IYCF intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IYCF intervention (behaviour change modules and small-quantity lipid-based nutrient supplements from 6 to 12 months of age)
Study: 36585408
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (0.1 mg/day) plus oral micronized progesterone (200 mg/day as 100 mg twice daily)
Study: 36585491
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen therapy (ET) and Placebo (PLC)
Study: 36585608
Drug: Withdrawal or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal or withholding of life-sustaining therapies
Study: 36585933
Drug: Internet-based exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based exposure therapy for fibromyalgia (10 weeks)
Study: 36586351
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimethyl fumarate treatment (DMF)
Study: 36586514
Drug: 30-mg oral
Normalized name: dacomitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-mg oral melatonin
Study: 36586583
Drug: 0.5%, 0.75%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5%, 0.75%, or 1.5% ruxolitinib cream applied twice daily for 28 days
Study: 36587890
Drug: Subcutaneous C.E.R.A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous C.E.R.A. administration every 4 weeks
Study: 36588113
Drug: PBM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBM treatment (590, 660 and 850 nm) 3 times per week over 3-4 weeks (9 treatments per series)
Study: 36588113
Drug: PBM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBM treatment
Study: 36588113
Drug: PBM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBM treatment and sham treatment
Study: 36588137
Drug: Risankizumab 300
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab 300 mg
Study: 36588741
Drug: Ganshuang granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganshuang granule combined with tenofovir; dosage and duration not available
Study: 36590787
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg over 40 min)
Study: 36590789
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 mg) once daily for 10 days
Study: 36591610
Drug: Optimised treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised treatments
Study: 36591610
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy containing metronidazole, tetracycline and bismuth
Study: 36591610
Drug: Triple amoxicillin-levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple amoxicillin-levofloxacin therapy
Study: 36591610
Drug: Overall treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatments
Study: 36591636
Drug: Videoconferencing acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videoconferencing acceptance and commitment therapy (ACT)
Study: 36592299
Drug: High-dose cephalexin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cephalexin (1000 mg)
Study: 36592299
Drug: Standard-dose cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cephalexin (500 mg)